KB707-02 A Phase 1/2 Study of Inhaled KB707 in Patients With Advanced Solid Tumor Malignancies Affecting the Lungs

by Mary Beth Wilwerding | Sep 3, 2026

MP0712-CP101 A phase 1/2a study to assess safety, tolerability, and efficacy of [212Pb]Pb-DOTAM-MAM279 in patients with small cell lung cancer and other DLL3 expressing solid tumors

by Mary Beth Wilwerding | Aug 19, 2026

NEO-811-101 An Open-Label, First-in-Human, Phase 1/2 Dose Escalation and ExpansionStudy of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable ClearCell Renal Cell Carcinoma​

by Mary Beth Wilwerding | Aug 19, 2026

OM-GRPR1 A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors

by Mary Beth Wilwerding | Aug 19, 2026

P300-02-001 A Phase 1b/2a, Multicenter, Open-Label Study of Pocenbrodib as Monotherapy and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

by Mary Beth Wilwerding | Aug 19, 2026